Stewart A - Search Results

1

New treatment options for multiresistant gram negatives.

Paterson DL, Isler B, Stewart A. Paterson DL, et al. Among authors: stewart a. Curr Opin Infect Dis. 2020 Apr;33(2):214-223. doi: 10.1097/QCO.0000000000000627. Curr Opin Infect Dis. 2020. PMID: 32068644 Review.

2

The Use of Therapeutic Drug Monitoring to Optimize Treatment of Carbapenem-Resistant Enterobacter Osteomyelitis.

Stewart A, Graves B, Hajkowicz K, Ta K, Paterson DL. Stewart A, et al. Microb Drug Resist. 2015 Dec;21(6):631-5. doi: 10.1089/mdr.2015.0006. Epub 2015 Jul 14. Microb Drug Resist. 2015. PMID: 26171974

3

Treatment of Infections by OXA-48-Producing Enterobacteriaceae.

Stewart A, Harris P, Henderson A, Paterson D. Stewart A, et al. Antimicrob Agents Chemother. 2018 Oct 24;62(11):e01195-18. doi: 10.1128/AAC.01195-18. Print 2018 Nov. Antimicrob Agents Chemother. 2018. PMID: 30104282 Free PMC article. Review.

4

Modern Clinician-initiated Clinical Trials to Determine Optimal Therapy for Multidrug-resistant Gram-negative Infections.

Stewart AG, Harris PNA, Chatfield M, Evans SR, van Duin D, Paterson DL. Stewart AG, et al. Clin Infect Dis. 2020 Jul 11;71(2):433-439. doi: 10.1093/cid/ciz1132. Clin Infect Dis. 2020. PMID: 31738398

5

Evaluation of quick sequential organ failure assessment and systemic inflammatory response syndrome in patients with gram negative bloodstream infection.

McNamara JF, Avent M, Stewart A, Kwan C, Paterson DL. McNamara JF, et al. Among authors: stewart a. Infect Dis Health. 2020 Aug;25(3):151-157. doi: 10.1016/j.idh.2020.01.003. Epub 2020 Jan 28. Infect Dis Health. 2020. PMID: 32005586

6

Oral cephalosporin and β-lactamase inhibitor combinations for ESBL-producing Enterobacteriaceae urinary tract infections.

Stewart AG, Harris PNA, Henderson A, Schembri MA, Paterson DL. Stewart AG, et al. J Antimicrob Chemother. 2020 Sep 1;75(9):2384-2393. doi: 10.1093/jac/dkaa183. J Antimicrob Chemother. 2020. PMID: 32443141

7

Achromobacter Infections and Treatment Options.

Isler B, Kidd TJ, Stewart AG, Harris P, Paterson DL. Isler B, et al. Antimicrob Agents Chemother. 2020 Oct 20;64(11):e01025-20. doi: 10.1128/AAC.01025-20. Print 2020 Oct 20. Antimicrob Agents Chemother. 2020. PMID: 32816734 Free PMC article. Review.

8

Is Ceftazidime/Avibactam an Option for Serious Infections Due to Extended-Spectrum-β-Lactamase- and AmpC-Producing Enterobacterales?: a Systematic Review and Meta-analysis.

Isler B, Ezure Y, Romero JLG, Harris P, Stewart AG, Paterson DL. Isler B, et al. Antimicrob Agents Chemother. 2020 Dec 16;65(1):e01052-20. doi: 10.1128/AAC.01052-20. Print 2020 Dec 16. Antimicrob Agents Chemother. 2020. PMID: 33046493 Free PMC article.

9

Erratum to: Oral cephalosporin and β-lactamase inhibitor combinations for ESBL-producing Enterobacteriaceae urinary tract infections.

Stewart AG, Harris PNA, Henderson A, Schembri MA, Paterson DL. Stewart AG, et al. J Antimicrob Chemother. 2021 Jan 1;76(1):281. doi: 10.1093/jac/dkaa424. J Antimicrob Chemother. 2021. PMID: 33111952 No abstract available.

10

An update on cefepime and its future role in combination with novel β-lactamase inhibitors for MDR Enterobacterales and Pseudomonas aeruginosa.

Isler B, Harris P, Stewart AG, Paterson DL. Isler B, et al. J Antimicrob Chemother. 2021 Feb 11;76(3):550-560. doi: 10.1093/jac/dkaa511. J Antimicrob Chemother. 2021. PMID: 33332545

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

5,161 results

Search Page